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O B J E C T I V E S Our aim was to image angiogenesis produced by endomyocardial injection of
phVEGF165 in a swine model of hibernating myocardium using [
123I]Gluco-arginine-glycine-aspartic acid
(RGD) targeting the v3 integrins.
B A C KG ROUND A noninvasive test to monitor the efﬁcacy of therapy inducing angiogenesis is
needed. The interaction between extracellular matrix and endothelial cells in sprouting capillaries is
effected primarily by v3 integrins that bind through RGD motifs.
METHOD S At 21  4 days, after left circumﬂex coronary artery ameroid constrictor placement, 8
swine received endomyocardial injection of 1.2 mg phVEGF165 divided into 6 sites and 6 swine received
saline (S) using nonﬂuoroscopic 3-dimensional endocardial mapping system (Noga)-guided delivery.
After 20  6 days, 13 animals were injected with 6.4  1.7 mCi [123I]Gluco-RGD, 1 VEGF (vascular
endothelial growth factor)-injected animal with I-123–labeled peptide control, and all animals with 2.5
 0.4 mCi of Tl-201 and underwent single-photon emission computed tomography imaging. Blood ﬂow
and echocardiographic measurements were made at both time points and tissue analyzed for ﬁbrosis
and capillary density by lectin staining.
R E S U L T S Hibernating myocardium in the ameroid constrictor territory at time of injections was
documented by reduced wall thickening compared with remote. Ratio of myocardial blood ﬂow in left
circumﬂex coronary artery/left anterior descending coronary artery territories increased by 15  11% in the
VEGF animals and fell 13  12% in S-injected (p  0.01). There was a small increase in wall thickening in
constrictor territory after VEGF (8  17%) while in S-injected animals wall thickening fell by 23  31% (p 
0.01 vs. VEGF). Lectin staining as percent positive tissue staining for ameroid territory was higher in
VEGF-injected compared with S-injected animals (2.5  1.5% vs. 0.87  0.52%, p  0.01). Focal uptake of
[123I]Gluco-RGD corresponding to Tl-201 defects was seen in VEGF-injected but not in S-injected animals.
[123I]Gluco-RGD uptake in the ameroid territory as percent injected dose correlated with lectin staining (R2
0.80, p  0.002).
CONC L U S I O N S These data suggest that single-photon emission computed tomography imaging
of radiolabeled RGD peptides may be a useful noninvasive method to monitor therapy that induces
angiogenesis in the heart. (J Am Coll Cardiol Img 2008;1:500–10) © 2008 by the American College of
Cardiology Foundation
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Universität Innsbruck, Innsbruck, Austria; and §Technische Universität München, Munich, Germany. This study was
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501pproaches to produce therapeutic angiogenesis
in patients with chronic ischemic myocar-
dium have included administration of re-
combinant human vascular endothelial
rowth factor (VEGF) protein into the coronary
rteries (1), administration of naked plasmid de-
xyribonucleic acid encoding for phVEGF2 in-
ected into the myocardium either with a thoracot-
my or percutaneously using a catheter-based
yocardial injection and mapping system (Biosense-
ebster, Irwindale, California) (2–5), and intra-
oronary injection of genes encoding for VEGF
6–8). The results of clinical trials have been mixed.
See page 511
nitial experience with cell-based therapy (CD34
one marrow-derived cells) has shown some efficacy
n early trials. In the absence of strong evidence to
upport transformation of these progenitor cells
nto myocytes, a mechanism proposed for observed
enefits is release by these cells of cytokines includ-
ng VEGF (9,10). There is a need to develop a
oninvasive test to monitor the efficacy of therapy
hat directly or indirectly induces angiogenesis.
The interaction between the extracellular matrix
nd endothelial cells is affected by a family of cell
dhesion receptors (integrins) that bind to cells in
prouting capillaries (11,12). The v3 integrin
eceptor has been identified as a principle integrin
xpressed in neovascular growth (13–16). Binding
f cells to the extracellular matrix occurs through
rginine-glycine-aspartic acid (RGD) motifs on
igands. This observation forms the basis for devel-
pment of radiolabeled ligands with RGD motifs
17). Haubner et al. (18–20) improved pharmaco-
inetics of v3 selective first-generation tracers by
lycosylation of a modified derivative using sugar
mino acid to achieve decreased lipophilicity and
ecreased hepatic uptake. It was the purpose of this
tudy to test the hypothesis that angiogenesis pro-
uced by endomyocardial injection of phVEGF
165
in
swine model of hibernating myocardium can be imaged
sing [123I]Gluco-RGD targeting the v3 receptors on
mooth muscle cells that bind components of the extra-
ellular matrix during capillary sprouting.
ETHODS
or all experiments, conditioned castrated male
uvenile swine weighing 20 to 30 kg were used. All
xperiments were performed within the National
nstitutes of Health Guidelines for the Care and Vse of Laboratory Animals and with the approval
f the Rhode Island Hospital Animal Care Com-
ittee. Upon arrival at the Animal Care Facility, all
tudy animals were fed a standard pig chow.
urgery. The left thoracotomy approach was used
or placement of single left circumflex coronary
rtery ameroid. The left atrial appendage was lifted
nd a 1-cm segment of the proximal circumflex
rtery was dissected free from the surrounding
yocardial tissue. The arterial segment was care-
ully lifted using silk suture at the proximal and
istal ends and the carefully sized ameroid (Re-
earch Instruments, Escondido, California) placed
nugly around the artery but not constricting it. The
meroid size for most of the experiments was 2.75
m (range 2.50 to 3.00) with a gap size of 0.8 mm.
he left atrial appendage was then released and the
ericardium loosely closed. A chest tube was placed
n the chest cavity, exiting through the
kin. After re-expansion of the left lung
nd re-establishment of negative chest
ressure, anesthetics were discontinued
nd the animal was allowed to awaken.
nimals received daily oral antibiotics for
days.
oga mapping and intramyocardial injec-
ion. After 2 to 3 weeks, animals were
nesthetized and a midline neck incision
ade exposing the right carotid artery and
nternal jugular vein. A 9-F sheath was
laced in the artery and a catheter placed
nto the vein. Coronary angiography was
erformed through the carotid artery fol-
owed by transthoracic echocardiography.
n Agilent 5500 Sonos platform (Philips,
ndover, Massachusetts) with a phased
rray 2- to 4-MHz probe was used. Animals were
ositioned supine and imaged in 4 standard imag-
ng planes: parasternal long-axis, parasternal short-
xis, apical 4-chamber, and apical 2-chamber views.
Endocardial R-wave mapping was then per-
ormed using a nonfluoroscopic 3-dimensional en-
ocardial mapping system (Noga) (Johnson &
ohnson, Biosense-Webster, Diamond Bar, Cali-
ornia). A reference was centered over the heart
sing the graphics workstation. The mapping cath-
ter was passed through the carotid sheath and
dvanced into the left ventricular (LV) cavity. The
osition of the catheter tip was located in
-dimensional space. The stability of the catheter-
o-wall contact was evaluated at every site. With
oga-guided placement, 6 injections (1 ml) of
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502rea) in 8 animals and saline in 6 animals (control
roup). A catheter was placed in the LV, and 1
njection of colored microspheres was given to
ocument blood flow. The sheath was removed and
he carotid artery repaired.
inal study. Two weeks after intervention, the ani-
al was returned to the Cardiovascular Research
aboratory for the final study. Coronary angiogra-
hy was first performed followed by electromechan-
cal mapping of the heart to obtain 60 to 90 points.
chocardiography was performed followed by in-
ection of thallium-201 (2 to 3 mCi) and v3-
elective [123I]Gluco-RGD in 13 animals and 123I-
abeled negative control peptide in 1. One to 2 h
ater (based on blood pool clearance of [123I]Gluco-
GD), 2 sequential tomographic scans were per-
ormed without moving the animal on an ADAC
rc 3000 camera interfaced with a Nuclear Mac
Nuclear Cardiology Systems, Boulder, Colorado)
ver 180° orbit at 30 s per stop for 32 stops using
he 70 keV photopeak and 15% window for Tl-201
nd 160 keV photopeak with 15% window for
-123.
At completion of all the imaging procedures,
nesthesia was deepened and the animal sacrificed
ith a bolus of potassium chloride and the heart
emoved. The heart was “breadloaf sliced” and
maged ex vivo on the detector for I-123. Tissue
amples were removed from the heart for weighing,
taining, fibrosis measurement, and blood flow
nalysis.
racer preparation, injection, and imaging. The label-
ng precursor used was v3-selective glycopeptide
yclo(-Arg-Gly-Asp-D-Tyr-Lys[SAA]) (Gluco-
GD) where SAA stands for sugar amino acid,
hich is in this case is 3-acetamido-2,6-anhydro-
-deoxy--D-glycero-D-gulo-heptanoic acid (18).
luco-RGD (200 to 300 g; molecular weight
50.9 g/mol) was dissolved in phosphate buffered
aline and transferred to an Eppendorf cap coated
ith Iodogen. Approximately 25 mCi of carrier
dded 123I-iodine (2  108 GBq/mol) (MDS
ordion, Ottawa, Ontario, Canada) was added.
fter 30 min at room temperature, the solvent was
emoved from the solid oxidizing agent. The la-
eled compound was separated from precursor by
igh pressure liquid chromatography (HPLC). The
PLC conditions were 0% to 40% acetonitrile in
ater with 0.1% trifluoro acetic acid with flow of 1
l/min, UV detection at 220 nm and 20 min
radient, using a Nucleosil C-18 5 m, 125  4.6
m column (Capital HPLC Ltd., West Lothian,
cotland, United Kingdom). The precursor has a setention time of 13 min and [123I]Gluco-RGD of
6 min. The 2 peaks were well separated. The
pecific activity was determined by the specific
ctivity of the radioisotope. The solvent was re-
oved before injection. The radiochemical yield
as about 50%. Activities of 25 mCi resulted in
pproximately 13 mCi [I-123]Gluco-RGD. The
egative control peptide, cyclo(-Arg-Ala-Asp-D-
yr-Val-) was labelled using the same protocol as
escribed for Gluco-RGD.
uclear data processing. The raw tomographic nu-
lear data were processed using standard software.
he thallium and [123I]Gluco-RGD scans were
oregistered in polar map display format to display
he relative distributions of the 2 tracers in each
eart. The percent injected dose (ID) was calculated
rom the decay corrected injected activity, I-123
ounts in the ameroid territory, tissue weight, and
amera efficiency.
chocardiographic data processing. Analysis of LV
lobal and segmental function was performed by
xperts blinded to the results of other imaging modal-
ties and to pathology. Regional wall thickening was
easured off-line using digital calipers for 4 equal
egments (septal, anterior, lateral, and posterior) from
he midshort-axis view. Wall thickening for each
egment was calculated as percentage change in wall
hickness from end diastole to end systole. Global left
entricular ejection fraction (LVEF) was calculated
sing a Simpson’s rule algorithm.
-wave voltage map processing. Post-processing of
he endocardial map was done using the Biosense
ork station. The final map for each animal was
elected and displayed. The apex location was
hecked for accuracy, and the map was played back
n cine (motion) mode. Poor points were deleted
sing established criteria.
issue processing and image analysis. The heart was
repared for histology and microsphere measure-
ents in the following manner. Each 1-cm bread-
oaf slice was divided into anterior, septal, posterior,
nd lateral regions. The slices were traced and the
racings annotated for localization of sample
ources. Samples were taken from each region for
icrosphere counting. Weights from the lateral
all samples were used for the ID calculations. Two
-m sections from each of the 4 anatomical
egions (anterior, septal, posterior, and lateral) from
ach 1-cm slice were taken for fibrosis measure-
ents. Each 4-m section was mounted and
tained with trichrome. Each stained section was
canned into a computer and imported into Photo-
hop. Color channels for each image were split.
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503mage math function in National Institutes of
ealth Image was used to quantify the percentage
brosis and irreversibly damaged myocytes for each
egion (21).
To identify capillary sprouting, a 5-m transmural
issue block was taken from the injection region for
ectin staining. Dolichos biflorus lectin is a glyco-
rotein capable of recognizing and binding to carbo-
ydrate moieties on endothelial cell membranes of
prouting capillaries. It was biotinylated to link with
treptavidin-horseradish peroxide, which links to 3,3=-
iamonobenzadine (brown chromagen). Sections
ere stained with 3,3=-diamonobenzadine and coun-
erstained with hematoxylin. Ten fields were ran-
omly captured at 20 from 3 different slides. Using
mage Pro Plus (Media Cybernetics, Inc., Silver
prings, Maryland), the brown DAB color (lectin)
as defined as was the entire field of tissue (blue). The
ombined areas for all 10 fields positive for lectin
taining were expressed as percent lectin-positive
taining over total tissue area. To identify vitronectin
eceptors in the injection site, v3 staining was
erformed on sections from 1 experiment injected
ith VEGF showing uptake of gluco-RGD and from
experiment injected with saline. For fluorescent
taining, the v3-fluorescein antibody was applied
Vitronectin receptor, clone LM609, Chemicon, Te-
ecula, California). The tissue was fixed in acetone
nd blocked with 0.3% of H2O2 in methanol. The
rimary antibody was applied in a dilution of 1:100
Vitronectin receptor, clone LM609, Chemicon), in
n overnight incubation. Staining was validated with
ositive control in kidney tissue and negative control
ith FITC-labeled IgG in porcine myocardium.
lood ﬂow measurements. Colored microspheres
15  0.43 m) used for blood flow determination
ere cross-linked polystyrene-divinylbenzene mi-
rospheres in 8 colors: red, blue, orange, green,
ellow, coral red, violet, and black (E-Z Trac, Los
ngeles, California). These colored microspheres
re chemically stable and exhibit no dye leaching,
ven in tissue exposed to strong acid and base
olutions. Regional myocardial blood flow values
ere measured by using the methods described by
ale et al. (22) and as reported previously for our
aboratory (23).
tatistical analysis. Numeric data for the 2 groups
VEGF and saline injected) were compared using a
-sample t test with equal variance. All results are
xpressed as  SD. The myocardial uptake of
123I]Gluco-RGD for each heart was plotted
gainst the percent lectin staining using a simple
inear regression.ESULTS
meroid constrictors. Ameroid constrictors were
laced on circumflex arteries in 14 swine. The mean
ime between ameroid placement and VEGF injec-
ion was 21  6 days, and the mean time between
EGF injection and the final imaging and sacrifice
as 20  6 days. The initial weight was 25  5 kg,
nd the final weight was 49  9 kg. For the 8
EGF-injected animals, 6 of 8 ameroids were
atent at the time of injection and 5 of 8 were
atent at the final study with collaterals present in 2
f 3 of the closed vessels. For the 6 saline-injected
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Figure 1. Documentation of Hibernating Myocardium
All swine underwent unipolar voltage (UPV) mapping (top
panel), myocardial blood ﬂow (MBF) measurements with micro-
spheres (middle panel), and transthoracic echocardiography
(bottom panel) before myocardial injection of either phVEGF125
or saline. The UPV scores from the Noga map in the ameroid
territory were reduced compared with those in the remote myo-
cardium but in the viable range. MBF in cc/g/min was mildly
reduced in the ameroid territory compared with that in the
remote myocardium. The percent wall thickening in the ameroid
territory was reduced compared with that in the remote myo-
cardium. These ﬁndings of abnormally functioning but viable
myocardium fulﬁll the criteria for hibernation.
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504nimals, 4 to 6 ameroids were patent at time of
njection and 3 of 6 were patent at the final study
ith collaterals seen in one. Hibernation in the
ircumflex territory was supported by comparing
-wave amplitude, myocardial blood flow, and wall
hickening in the circumflex territory to remote
yocardium as shown in Figure 1. While wall
hickening was reduced in the ameroid territory,
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Figure 2. Change in Blood Flow Ratios in VEGF-Injected and
Control Animals
Myocardial blood ﬂow (MBF) is expressed as ratio of MBF in the
ameroid territory to remote territory. The change ( SD) from
immediately before intramyocardial injection of either
phVEGF165 or saline to 3 weeks after injection for both treat-
ment and control experiments are expressed as percent. The
blood ﬂow ratio increased in the vascular endothelial growth
factor (VEGF)-injected animals (orange bar) and decreased in
the saline-injected animals (yellow bar). LAD  left anterior
descending coronary artery; LCx  left circumﬂex artery.
Figure 3. Change in LV Function Over Time
Global and regional left ventricular (LV) function were measured us
intramyocardial injection with either phVEGF125 (yellow bars) or sal
(LVEF) increased slightly but with a large standard deviation (error
also with a large standard deviation. Wall thickening (WT) in the am
factor (VEGF)-treated animals and fell in the saline-treated animals.-wave amplitude was within “viable” range, and
yocardial blood flow was mildly reduced com-
ared with that in the remote myocardium.
lood ﬂow and LV function. Transmural myocardial
lood flow in the ameroid territory increased by
.63  0.35 cc/gm/min between injection and final
tudy in animals injected with VEGF, and fell by
.14  0.34 cc/gm/min in animals injected with
aline (p  0.004). The ratios of blood flow in the
ateral wall (ameroid territory) over the remote
yocardium at baseline were not different between
EGF- and saline-injected animals (0.96  0.15
s. 1.09  0.02, p  0.12). Ratios increased after 3
eeks in the VEGF-injected animals (15  11%)
nd decreased in the saline-injected animals (13
12%) (p  0.006) (Fig. 2).
Baseline global and regional LV function was not
ifferent between the 2 groups: LVEF was 59 
1% for the VEGF group, and 51  15% for the
aline group (p  0.28); percentage anterior wall
hickening was 40  30% for the VEGF group and
5  31% for the saline group (p  0.38), and
ercentage lateral wall thickening was 35 18% for
he VEGF group and 45  25% for the saline
roup (p  0.55). LV function improved slightly
etween the 2 studies in the VEGF-injected ani-
als but continued to deteriorate in saline-injected
nimals. The percentage change in LVEF in the
EGF-injected animals was 4.3  9.0% and for
he saline-injected animals was 11.4  12.5%.
hile this difference was statistically significant
p  0.04), there was a wide range in values. In the
echocardiography immediately before and 3 weeks after
(orange bars). Mean value for left ventricular ejection fraction
while mean value for LVEF fell in the saline-treated animals but
id territory increased slightly in the vascular endothelial growthing
ine
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505EGF-injected group, 5 experiments showed no
hange in LVEF and 3 showed an increase while in
he saline-injected group; only 1 showed no change
nd 5 fell. There was a small increase in wall thick-
ning in the ameroid territory after VEGF (8 17%),
hile, in the saline-injected animals, wall thickening
ell by 23  31% (p  0.01 vs. VEGF) (Fig. 3).
ibrosis and angiogenesis. Fibrosis in the ameroid
erritory (as percent of the transmural sections) was
igher in the saline-injected animals than in the
EGF-injected animals (6.2  1.9% vs. 3.9 
.6%) (p  0.007). Histopathological evidence for
eovascularization in the VEGF-injected animals
ompared with that in the saline injected was
ocumented by lectin-positive staining (2.50 
.5% vs. 0.87  0.52%, p  0.01) (Fig. 4). The
EGF-injected tissue stained for vitronectin recep-
ors from several experiments showed positive flu-
rescence compared with saline-injected tissue (Fig.
Figure 4. Immunohistology Documenting Angiogenesis in VEGF
Values from quantitative immunohistology in the ameroid territory
(yellow bars) and saline-injected animals (orange bars) are shown
sis and greater capillary sprouting by lectin staining than the saline
tive examples of tissue staining. Panel A shows a myocardial sectio
experiment, and panel B shows 1 saline-injected animal. Brown sta
panel B. Panel C shows green ﬂuorescence identifying integrin exp
animal that showed in-vivo uptake of [123I]Gluco-RGD. FITC  ﬂuor). Supporting the pathology were the Noga map andings that showed improvement in the R-wave
oltage in the VEGF-injected territory compared
ith reduction in the saline-injected territory (Fig. 5).
can results. Blood pool clearance curve of the
adiolabeled peptide showed blood levels below
0% of peak by 2 h after injection. All animals
howed mild resting thallium defects in the ameroid
erritory. The VEGF-injected animals showed focal
ptake of [123I]Gluco-RGD in the same territory
hile none of the saline-injected animals or the
adiolabled control peptide showed focal uptake of
adiotracer in the heart (Fig. 6). There was no
ifference in thallium uptake as percentage peak
ounts in the ameroid territory between VEGF-
njected and saline-injected myocardium (0.78 
.07 vs. 0.70  0.09, p  0.12). The ratio of I-123
ounts in the ameroid territory to remote myocar-
ium was 1.71  0.11 for the VEGF-injected
nimals versus 1.04  0.13 for the saline-injected
ected Animals
he vascular endothelial growth factor (VEGF)-injected animals
e upper panel. The VEGF-injected experiments showed less ﬁbro-
cted control experiments. The bottom images show representa-
ained for lectin from the injection territory from 1 VEGF
g of sprouting capillaries is seen in panel A and is absent in
ion in capillary sprouts from the injection site of 1 VEGF-injected
in.-Inj
for t
in th
-inje
n st
inin
ressnimals (p  0.001). The counts per gram in the
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506njection site were higher for the VEGF-injected
nimals than for the saline-injected animals (180 
53 vs. 51  14) but the difference was not
ignificant while the percent ID, also higher in
EGF-injected animals than in the saline-injected
nimals (0.26  0.09 vs. 0.15  0.07  103), was
orderline significant (p  0.04). The difference in
ounts per gram between the 2 groups was not
ignificant, and the difference in percent ID was
orderline significant (p  0.04). When values for
he percent ID (per gram tissue) for the 11 exper-
ments in which all data for these calculations were
vailable were plotted against quantitative lectin
taining in the corresponding myocardial segments,
here was a significant correlation (R2  0.80, p 
.002) (Fig. 7). There was, however, overlap be-
Figure 5. Noga Maps and Unipolar Voltage Score in VEGF-Inject
Images shown on the left are unipolar voltage maps at the time of
and 1 vascular endothelial growth factor (VEGF)-injected animal. Th
the same 2 animals. The color bar in the right upper corner of eac
to 15 mV (pink). The saline-injected region shows a fall in unipolar
unipolar voltage score.ween the 2 groups. One of the saline-injected mnimals showed higher myocardial background up-
ake of [123I]Gluco-RGD and 1 of the VEGF-
njected animals had a low percent ID correspond-
ng to lower lectin staining.
I SCUS S ION
he present study is the first to image angiogen-
sis using a radiolabeled cyclo-RGD peptide
argeting v3 receptors in VEGF-injected hi-
ernating myocardium. Ameroid placement in
wine produced myocardial hibernation/stunning
ased on reduced regional wall thickening with
reserved R-wave voltage and mildly reduced myo-
ardial blood flow. Focal uptake of [123I]Gluco-
GD was seen on single-photon computed to-
and Control Animals
ction with the injection sites marked for 1 saline-injected animal
Noga maps on the right were acquired during the ﬁnal study on
age corresponds to unipolar voltage values from 6 mV (orange)
age score, while the VEGF-injected region shows an increase ined
inje
e 2
h im
voltography (SPECT) imaging corresponding to
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507egions of phVEGF165 injection at approximately
weeks after injection in treated animals. No
racer uptake was seen in the ameroid territory of
aline injection. Tracer uptake corresponded to
ocumentation of v3 receptors and lectin
taining for capillary sprouting in tissue samples
rom VEGF-injected territory. Myocardial blood
ow and LV function improved in VEGF in-
ected animals. These data suggest that radiola-
eled Gluco-RGD probes may be useful to
onitor angiogenesis therapy in hibernating
yocardium.
Approaches to stimulate myocardial angiogen-
sis in patients with intractable angina who are
ot candidates for percutaneous transluminal cor-
nary angioplasty or coronary artery bypass graft-
ng have included intracoronary infusion or in-
ramyocardial injection of a growth factor gene or
rotein (1–8). None of these studies showed
nequivocal efficacy, and initial enthusiasm for
Figure 6. SPECT Scans for RGD-Based Targeting of Neoangiogen
On the left are shown reconstructed short-axis (SA), vertical (VLA), a
(SPECT) slices from the thallium scans (top rows) and I-123 scans (b
endothelial growth factor (VEGF) and 1 animal treated with saline. T
and focal uptake of [123I]Gluco-RGD into the anterolateral wall. The
played on the polar maps. The saline-injected animal shows a mild-
of [123I]Gluco-RGD in the heart. RGD  arginine-glycine-aspartic acihese approaches has been tempered. Subsequent Vrials of stem cell therapy in myocardial infarction
o not support the role of these cells to differen-
iate into and function as myocytes but do seem
o support a paracrine effect of the engrafted cells
hrough secretion of VEGF in response to hypoxia
10,11). These findings renew interest in develop-
ng approaches to noninvasively monitor myocardial
ngiogenesis by targeting VEGF expression.
Approaches to image angiogenesis in the heart
r blood vessel wall have been reported using
ifferent imaging platforms (24–28). Targeting
olecular species expressed during angiogenesis
ith imaging probes has been investigated for
ancer and cardiovascular applications. VEGFs
re widely distributed in mammalian tissues. The
ember of the VEGF family that plays an
mportant role in angiogenesis is VEGF-A.
hese cytokines are expressed in response to
p-regulation of hypoxia-inducible factor-1.
n response to hypoxia, m-RNA encodes
s
horizontal long-axis (HLA) single-photon computed tomography
m rows) from 1 representative animal treated with vascular
VEGF-injected animal shows a mild anterolateral thallium defect
calization of the thallium defect and focal hotspot is better dis-
oderate anterolateral and apical defect without focal uptake ofesi
nd
otto
he
colo
to-mEGF molecules with 121, 145, 165 amino acid
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508equences (29). For capillary sprouting to occur,
here needs to be an interaction between the
ndothelial cell growth and the surrounding sup-
orting tissue or extracellular matrix. This inter-
ction necessary for new growth is mediated by
he integrins, a family of cell surface receptors
hat recognize extracellular matrix proteins such
s vitronectin, fibrinogen, and fibronectin and are
ecessary for optimal activation of growth factor
roteins (12–16).
Integrins are heterodimeric transmembrane gly-
oproteins consisting of an alpha and beta subunit
11,12). The integrins aggregate with growth factor
eceptors and thereby facilitate their activation.
ertain integrins are preferentially associated with
pecific growth factor receptors. The integrin v3
s associated with platelet-derived growth factor and
EGF receptors (13). This important role of v3
n promoting the binding of growth factor receptor
nd ligand has made it an important target for
evelopment of agents to image angiogenesis. Ex-
racellular matrix proteins like vitronectin, fibrino-
en, and fibronectin interact with the integrins via
he amino acid sequence RGD (16). Haubner et al.
18) were the first to report the synthesis and
iological evaluation of the first glycoslylated
GD-containing peptides (18). In this study we
sed Gluco-RGD and labeled it with iodine-123
Quantitative Lectin Staining (% area)
0.0 2.0 4.0
y = 0.049x + 0.0263
R2 = 0.7975
6.0 8.0 10.0
[123I]Gluco-RGD Uptake Versus Angiogenesis
ws percent injected dose (ID) per gram of tissue for [123I]Gluco-
d versus lectin staining as percent area for vascular endothelial
tor-injected animals (yellow triangles) and saline injected
uares). Although the relationship is signiﬁcant, there is not a
aration between the 2 groups. One saline-injected animal
focal hotspot in the myocardium but showed a higher level of
d activity for I-123. One of the vascular endothelial growth
ted experiments had low uptake of [123I]Gluco-RGD, which
ed to lower levels of angiogenesis by lectin staining. RGD 
ycine-aspartic acid.19). Direct halogenation involves a multistep prepa- tation and requires HPLC, and in vivo dehalogena-
ion degrades image quality. Subsequent to the com-
letion of this project, additional peptide compounds
ave been synthesized and tested in vivo in tumor
odels. These compounds include versatile chelating
oieties that allow linkage with both SPECT and
ositron emission tomography (PET) tracers (17).
hey are based on cyclic pentapeptide conjugated via
he -amino function of a lysine with chelators or use
n v3 binding disulphide-bridged undecapeptide
oupled with 6-hydrazinopyridine-3-carboxylic acid
nd labeled with 99mTc.
The use of probes containing the RGD motif to
mage angiogenesis has been reported for nuclear
SPECT and PET) applications and for magnetic
esonance imaging (24–28). Myocardial imaging of
ngiogenesis has been reported in a rat and dog
odel of chronic myocardial infarction using an
n-111-labeled v3-targeted agent (111In-RP748)
or v3 and thallium-201 for perfusion (26). Dual
sotope SPECT imaging showed focal uptake of
11In-RP748 in regions of reduced perfusion corre-
ponding to regions of angiogenesis by histological
nd immunohistological analysis (27). A PET ap-
roach to myocardial imaging using dual imaging
or both gene expression and angiogenesis was
eported (28). In this study, a nonreplicating ade-
ovirus expressing mutant herpesviral thymidine
inase (HSV1-sr39tk) reporter gene and human
EGF121 gene was constructed and injected into
ormal pig myocardium. Two days later, animals
ere injected with [18F]fluoro-hydroxymethyl-
utylguanine probe for the reporter gene and
18F]Galacto-RGD for angiogenesis. This novel
pproach documented reporter gene expression, but
here was no significant uptake of the [18F]Galacto-
GD probe. This failure to detect angiogenesis in
he normal porcine myocardium was attributed to
nsufficient time to allow angiogenesis to occur, but
ack of a hypoxic environment may have contrib-
ted. The ameroid model of chronic myocardial
schemia/hibernation may create a substrate for ex-
ression of related genes favorable to angiogenesis.
The swine model of hibernating myocardium pro-
uced by slow constriction of a coronary artery was
eveloped by Fallavollita et al. (30). Swine ameroid
odels have been used in pre-clinical studies to
ocument angiogenesis. A proof of concept paper by
ale et al. (31,32) showed that direct injection into the
yocardium of phVEGF165 could be performed us-
ng nonfluoroscopic electromechanical LV mapping
o localize hibernating myocardium and record injec-%
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509y Western blots in the injection sites, and in a
ubsequent paper the same group showed improve-
ent in collateral myocardial blood flow (33).
ONCLUS IONS
n these experiments, naturally occurring angiogen-
sis in response to hypoxia was not observed in the
aline-injected animals based on either lectin stain-
ng or detectable uptake of [123I]Gluco-RGD. Fail-
re of the hypoxic stimulus to produce beneficial
evels of naturally occurring angiogenesis was also
ndicated by failure to show improvement in perfu-
ion or LV function. A possible explanation for
hese findings is that the severity and/or duration of
issue hypoxia was insufficient stimuli to produce
therapeutic levels” of endogenous VEGF. The
onditions of these experiments were not designed
o address these questions.
Tracer retention in a region might be due to
irculating blood levels of compound at the time of
maging combined with differences in intramyocar-G, et al. Gene therapy (AGENT) trial signaling. Science 1ith changes in vascular permeability, and not
ctive angiogenesis. However, the correlation be-
ween lectin staining and percent ID supports actual
inding of the [123I]Gluco-RGD to v3 indicat-
ng growth factor activity. The study would have
een strengthened by evaluation of control hearts
ithout ameroids and treatment, and control hearts
ith phVEGF treatment. That the correlation
etween [123I]Gluco-RGD uptake and lectin stain-
ng does not show a perfect separation between the
EGF-injected and saline-injected animals indi-
ates that at least in one experiment high back-
round activity of 123I probably relating to in vivo
ehalogenation affected results. Peptides with more
table linkage to radio-probes including 111In and
9mTc via chelators have been developed for
PECT imaging. These new tracers eliminate this
roblem.
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